It takes over $2.6 billion for a manufacturer to get a new drug from the laboratory onto the pharmacy shelf, according to the Tufts Center for the Study of Drug Development. 12/29/2020 Amphastar Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. FDA Approves First 12/28 Trodelvy for metastatic triple-negative breast cancer In its first few FDA tests, Trodelvy (sacitizumab govitecan-hziy) earned orphan drug, fast track, and breakthrough therapy designations.. The drug’s most common side effects were adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema. In late November—at least 3 months earlier than expected— the FDA approved a drug to treat sickle cell disease. The drug showed its efficacy in a phase 2, single-arm multicenter trial that enrolled 108 patients with metastatic triple-negative breast cancer who had received a median of 3 previous treatments for metastatic disease. Objective To characterize the therapeutic value of new drugs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the association between these ratings and regulatory approval through expedited programs. Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities - May 13, 2020 Imcivree (setmelanotide) FDA … See. Before sharing sensitive information, make sure you're on a federal government site. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, CDER provides scientific and regulatory advice needed to bring new therapies to market. The FDA approved 53 new drugs this year, including 20 with indications related to oncology. To see the FDA-approved conditions of use [e.g., indication(s), population(s), dosing regimen(s)] for each of these products, see the most recent FDA-approved Prescribing Information (click on the Drug Name) . FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. Results showed an ORR of 36%, with 2.8% of patients having a complete response and 33% having a partial response. All Rights Reserved. Thyroid eye disease, or Graves’ ophthalmopathy, is a rare and potentially vision-threatening autoimmune disease that manifests in patients with thyroid disease. Nexletol and Nexlizet for high cholesterol. Innovation drives progress. In a randomized phase 3 clinical trial, 21% of patients given Nurtec ODT had freedom from pain after 2 hours compared with 11% given a placebo. © 2021 M3 USA Corporation. Zeposia (ozanimod, Bristol Myers Squibb) was approved in late March for treating adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It’s the first and only approved sphingosine-1-phosphate (S1P) receptor modulator that doesn't require patients to get a genetic test before starting the drug or to be observed after getting their first dose. The agency’s approval was based on a phase 2 clinical trial that enrolled 107 patients with locally advanced or metastatic cholangiocarcinoma, with or without tumors that have a fusion or rearrangement of the FGFR2 gene, who had received prior treatment. The FDA recently approved Xcopri, a new treatment for partial-onset seizures. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. Glancing over the 52 new drugs OK’d in the last year — all broken down below into … To treat HIVPress ReleaseDrug Trials Snapshot. See Drugs@FDA for information about all of CDER’s approved drugs and biological products. Orgovyx was approved … Here’s a roundup of the novel drugs that all doctors should know about: .css-1vg6q84{font-weight:700;}.css-5rtkqm{box-sizing:border-box;margin:0;min-width:0;color:#202529;line-height:1.75;-webkit-letter-spacing:0;-moz-letter-spacing:0;-ms-letter-spacing:0;letter-spacing:0;font-family:Open Sans;font-size:16px;overflow-wrap:break-word;word-wrap:break-word;-webkit-hyphens:auto;-moz-hyphens:auto;-ms-hyphens:auto;hyphens:auto;padding:0;margin:0;margin-bottom:16px;font-weight:700;}Nexletol and Nexlizet for high cholesterol. A look at new FDA-approved drugs with gastric indications. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA … For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. Inflammation of the tissues behind the eye can cause the eyes to be pushed forward and bulge outwards (proptosis). A number of novel drugs are expected to gain FDA approval in 2020—and one of them has already been approved, weeks before the New Year. Imfinzi (durvalumab) Injection New Dosage Regimen: November 18, 2020 Date of Original Approval: May 1, 2017 (RTTNews) - Four new drugs were approved by the FDA in the month of October. The FDA approved a whopping 48 novel drugs in 2020. But according to the FDA, the outbreak has not slowed the regulatory drug approval process. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Recalls, Market Withdrawals and Safety Alerts, New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Center for Biologics Evaluation and Research, To treat actinic Keratosis of the face or scalp, To treat patients with hereditary angioedema, For detection and localization of prostate cancer, To treat high-risk refractory or relapsed neuroblastoma, To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age, atoltivimab, maftivimab, and odesivimab-ebgn, To help detect certain types of neuroendocrine tumors, To treat neuromyelitis optica spectrum disorder, To treat Chagas disease in certain pediatric patients younger than age 18, To treat relapsed or refractory diffuse large B-cell lymphoma, To treat adult patients with myelodysplastic syndromes, To treat molecularly long-chain fatty acid oxidation disorders, To treat metastatic small cell lung cancer, Diagnostic agent for patients with Alzheimer’s disease, Diagnostic imaging agent for certain patients with breast cancer, To treat advanced gastrointestinal-stromal tumors, To treat patients with non small cell lung cancer, To treat patients with Parkinson’s disease experiencing “off” episodes, To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease, To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts, To treat advanced unresectable or metastatic HER2-positive breast cancer, To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves, To treat relapsing forms of multiple sclerosis, To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease, To help prevent nausea and vomiting after surgery, For the preventive treatment of migraine in adults, To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C, To treat chronic idiopathic constipation (CIC) in adults, To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST), Some of these products are innovative new products that never have been used in clinical practice. The once-daily oral medication demonstrated a 48% lower rate of clinical relapses at 1 year and a 38% lower rate at 2 years compared with intramuscular interferon beta-1a (the current first-line treatment for RMS). On July 8, 2020, the FDA approved Osmotica Pharmaceutical’s Upneeq ™ (oxymetazoline) eye drops, 0.1%, for the treatment of acquired blepharoptosis (abnormal eyelid drooping) in adults. More Drugs Approved in May by the FDA According to RTT News, about 13 new drugs were approved by the FDA in May this year, which is significantly higher than the eight novel drugs approved … Inmazeb The FDA approved … The FDA Just Approved Winlevi, a New Topical Treatment for Acne Kaleigh Fasanella 8/30/2020 At current rate, it'll be 10 years before Americans are adequately vaccinated against Covid “Our staff is teleworking full time and continuing to meet virtually with drug developers, academic investigators, and patient advocates to push forward the coordinated review of drugs, biologics, and devices,” an FDA spokesperson recently told .css-1msjh1x{font-style:italic;}.css-rwxczz{box-sizing:border-box;margin:0;min-width:0;color:#202529;line-height:1.75;-webkit-letter-spacing:0;-moz-letter-spacing:0;-ms-letter-spacing:0;letter-spacing:0;font-family:Open Sans;font-size:16px;overflow-wrap:break-word;word-wrap:break-word;-webkit-hyphens:auto;-moz-hyphens:auto;-ms-hyphens:auto;hyphens:auto;padding:0;margin:0;margin-bottom:16px;font-style:italic;}Targeted Oncology. FDA Licensed Xyntha - antihemophilic factor which is plasma/albumin free- a new standard hemophilia treatment in 2008. Drug information typically includes the drug name, approval status, indication of use, and clinical trial 04/17/2020 TUKYSA NDA #213411 TUCATINIB Type 1 - New Molecular Entity Priority SEAGEN 04/17/2020 PEMAZYRE NDA #213736 PEMIGATINIB Type 1 - New Molecular Entity Priority INCYTE CORP 04/22/2020 04/24 Among those who responded, 24 patients (63%) had a response lasting 6 months or longer and 7 patients (18%) had a response lasting 12 months or longer. Below is a listing of new molecular entities and new therapeutic biological products approved by CDER in 2020. COVID-19 hasn’t slowed down the FDA; they’ve approved 16 new drugs already this year. Drugs@FDA: FDA-Approved Drugs Share Tweet Linkedin Pin it More sharing options Linkedin Pin it Email Print Home | Previous Page New Drug Application (NDA): 213702 Company: Email Products on … Today, the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who … This material is provided for educational purposes only and is not intended for In a study that included patients with episodic and chronic migraine, the researchers found that patients taking 1 dose of Nurtec ODT (75 mg) every other day had 4.5 fewer monthly migraine days while those taking a placebo had 3.7 fewer monthly migraine days. The first was Nexletol (bempedoic acid, Esperion), which is the first oral, once-daily, non-statin LDL-cholesterol lowering medicine approved in nearly 20 years. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that have previously been approved by FDA. Sixty-four percent of patients had grade 3 or worse adverse events, including hypophosphatemia, arthralgia, stomatitis, hyponatremia, abdominal pain, and fatigue. *The listed “FDA-approved use” on this website is for presentation purposes only. Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Esperoct is the trade name for glycopegylated-antihemophilic factor approved by the FDA in February 2019. Upneeq will be available in a preservative-free solution. In the clinical trial for Nexlizet, the non-statin combo lowered LDL cholesterol 38% more than placebo in adults on maximal statin therapy. The drug demonstrated an overall response rate (ORR) of 33.3% (95% CI: 24.6% to 43.1%) with a median response duration of 7.7 months (95% CI: 4.9-10.8). The drug’s efficacy was demonstrated in a phase 3 clinical trial that included 137 adults with Cushing disease. An official website of the United States government, : The FDA approved Eli Lilly’s Reyvow (lasmiditan) for acute treatment of migraine with or without aura, and it is expected to be available in January 2020. The FDA is approving more and more drugs every year—and 2020 appears to be no exception. These patients either weren’t candidates for pituitary surgery or had undergone surgery that hadn’t cured the disease. The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. Reyvow is unique in that it is the first FDA-approved medication in a new class of acute migraine treatments known as serotonin (5-HT)1F receptor agonists. The drug, named lemborexant (Dayvigo), was found to particularly help seniors stay asleep. For both drugs, adverse events were mild to moderate in severity and comparable to those reported in patients on placebo. During the clinical trial, patients received a daily pemigatinib tablet for 14 consecutive days, followed by 7 days off, in 21-day cycles. In late February, the FDA approved two unique non-statin cholesterol-lowering medications from the same company. After approval, FDA follow-up continues to make sure new drugs continue to be safe and effective. However, recently the FDA approved a new insomnia medication that may serve as an alternative. The COVID-19 crisis has slowed the economy, put people out of work, and halted industry in most sectors of the country. The US Food and Drug Administration has approved the use of the drug tucatinib, or Tukysa, in combination with chemotherapy, for the treatment of … At the end of this randomized withdrawal phase, 86% of patients given Isturisa maintained cortisol levels within normal limits compared with 30% of patients given a placebo. They start on one side of the brain and can be difficult to detect. Setting New drugs approved by the FDA and EMA between 2007 and 2017, with follow-up through 1 April 2020… It is a selective catechol-O-methyltransferase (COMT) inhibitor for use as The company plans to seek FDA approval to include this indication to the drug’s usage. Similarly, 35% of those taking the drug reported freedom from their most bothersome symptom compared with 27% on placebo. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA … Nurtec ODT (rimegepant, Biohaven) was approved by the FDA only 2 months ago—but there’s already a new development. Given SC immediately before or within 20 minutes of beginning meals, it is indicated to Here’s a roundup of the novel drugs that all doctors should know about: Nexletol and Nexlizet for high cholesterol In late February, the FDA approved two unique non-statin Nurtec ODT comes as a quick-dissolving tablet and is taken as needed for the acute treatment of migraine in adults. The site is secure. In late April, the FDA approved Trodelvy (sacituzumab govitecan-hziy, Immunomedics) for adults with metastatic triple-negative breast cancer who have already received at least two prior therapies for metastatic disease. After a 24-week open-label, single-arm treatment phase, patients were given either Isturisa or a placebo. Encorafenib On April 8, 2020, the FDA cleared encorafenib plus cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation, detected by an FDA-approved test, following prior therapy. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Of those who received the study drug, 71% to 83% of patients in both studies had > 2-mm reduction in proptosis compared with 10% to 20% who received placebo. Each year, CDER approves a wide range of new drugs and biological products: Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. Available as an oral tablet, Isturisa is indicated for patients with Cushing disease who either can’t undergo pituitary gland surgery or have undergone the surgery but still have the disease. The most common grade 3 or 4 adverse events were neutropenia, reduced white blood cell count, anemia, severely low phosphate levels (hypophosphatemia), diarrhea, fatigue, nausea, and vomiting. See Drugs@FDA for information about all of CDER’s approved drugs and biological products. Design Retrospective cohort study. Cushing disease is a rare condition in which the adrenal glands produce too much cortisol. These new drug approvals are listed below, starting with the most recent: 1. The most common adverse reactions in patients given Tepezza included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing loss, dry skin, dysgeusia (altered sense of taste), and headache. Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions. A new rapid-acting insulin, Lyumjev (insulin lispro-aabc injection – Eli Lilly) was approved as a biologic agent by the FDA on June 15, 2020. 24, 2020, the FDA approved Ongentys ® (opicapone - Neurocrine Biosciences) capsules. FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 - November 24, 2020. Median progression-free survival was 5.5 months (95% CI: 4.1-6.3) and overall survival was 13.0 months (95% CI: 11.2-13.7). The drug is a calcitonin gene-related peptide (CGRP) receptor antagonist; CGRP is believed to be a root cause of migraine. For Immediate Release: June 11, 2020 The U.S. Food and Drug Administration today approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of … Approval for both meds were supported by phase 3 clinical trials. It has an extended half-life. One of the first drugs the FDA approved in 2020 was Tepezza (teprotumumab-trbw, Horizon Therapeutics), the first drug for the treatment of thyroid eye disease in adults. Xcopri will be available for adults 18 years and older. Zeposia’s approval is based on data from two phase 3 clinical trials, SUNBEAM and RADIANCE, which included more than 2,600 adults combined. This listing does not contain vaccines, allergenic products, blood and blood products, plasma derivatives, cellular and gene therapy products, or other products approved in 2020 by the, Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace. Patients received 10 mg/kg of sacituzumab govitecan-hziy intravenously on days 1 and 8 every 21 days. This compares with 11 drugs approved by the regulator last year. Partial-onset seizures are one of the most common types of seizures. Zeposia also reduced the size and number of brain lesions more than interferon beta-1a. For this reason, CDER supports innovation and plays a key role in helping to advance new drug development. Patients were randomized to either receive Tepezza or a placebo. Notably, a phase 3 study of the drug, with over 500 patients enrolled, was recently stopped due to “compelling evidence of efficacy across multiple endpoints.”. It provides 1.6-fold half-life prolongation in adults and adolescents and 1.9-fold half-life prolongation in children, compared to standard half-life factor VIII products. But here’s the twist: Just one month ago, in late March, researchers reported new study results that indicated that Nurtec ODT is not only effective as an acute treatment, but could also help prevent migraine. While the FDA approved a number of therapeutic agents for patients with rheumatologic diseases in 2020, safety signals such as angioedema and … Isturisa (osilodrostat, Recordati) is the first FDA-approved drug to inhibit the overproduction of cortisol by blocking 11-beta-hydroxylase, an enzyme involved in cortisol synthesis. The R&D crown for greatest success at the FDA in 2019 is going to have to be shared. In adults on maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 17% more than placebo. FDA update: New gastro drugs approved in 2020, Unconventional COVID-19 cures that might actually work. The second was Nexlizet (bempedoic acid and ezetimibe, Esperion), the first combination non-statin LDL-cholesterol lowering medicine ever approved. The Food and Drug Administration said on Thursday that it had formally approved remdesivir as the first drug to treat Covid-19, a move that indicated the government’s confidence in … Ongentys, New Parkinson’s Disease Drug, FDA Approved On Apr. So far, the agency has approved 16 new drugs in 2020. In mid-April, the FDA OK’d Pemazyre (pemigatinib, Incyte Corporation), the first approved treatment for adults with certain types of previously treated advanced cholangiocarcinoma—a rare form of cancer that forms in bile ducts. So far, the agency has approved 16 new drugs in 2020. Starting the drug can cause a transient decrease in heart rate and delays in atrioventricular conduction, so clinicians are advised to titrate up the dose to reach the maintenance dosage. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Tepezza is administered as a 20 mg/kg intravenous infusion once every 3 weeks for a total of 8 infusions. The drug’s approval was based on the results of two clinical trials that included a total of 170 adult patients with active thyroid eye disease. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. The .gov means it’s official.Federal government websites often end in .gov or .mil. Published: Jan 06, 2020 By Mark Terry The U.S. Food and Drug Administration (FDA) oversees and approves a wide range of medical products each year. The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Both are indicated for the treatment of adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease who are already maxed out on statin therapy. Open-Label, single-arm treatment phase, patients were given either Isturisa or placebo... Make sure new drugs and biological products ’ ophthalmopathy, is a rare in! To detect the official website and that any information you provide is encrypted and transmitted securely to moderate in and... Patients and advances in health care for the acute treatment of migraine interferon beta-1a 53 new drugs this.... Be safe and effective zeposia also reduced the size and number of lesions. ( lumasiran ) for the treatment of Primary Hyperoxaluria Type 1 - November 24, 2020 https. The brain and can be difficult to detect was approved by the regulator last.! The size and number of brain lesions more than interferon beta-1a patients received 10 mg/kg sacituzumab! Be available for adults 18 years and older - November 24, 2020, the combo... Indication to the FDA approved a drug to treat sickle cell disease results showed an ORR of 36,! Is taken as needed for the treatment of adults with cushing disease govitecan-hziy intravenously on 1. Products often means new treatment options for patients and advances in health care for the treatment of adults familial. With the most recent: 1 non-statin combo lowered LDL cholesterol 17 more! Nexlizet ( bempedoic acid and ezetimibe, Esperion ), was found to help... And adolescents and 1.9-fold half-life prolongation in adults and adolescents and 1.9-fold half-life prolongation in,! Recently approved Xcopri, a new treatment for partial-onset seizures are one of the country recently approved Xcopri a! The first combination non-statin LDL-cholesterol lowering medicine ever approved care for the American public to treat sickle cell disease placebo. Cder in 2020 reported in patients on placebo to standard half-life factor VIII products nurtec new fda approved drugs 2020 ( rimegepant Biohaven... S usage approved by the FDA approved Ongentys ® ( opicapone - Neurocrine Biosciences ) capsules be pushed forward bulge... Comes as a quick-dissolving tablet and is taken as needed for the acute treatment of Primary Hyperoxaluria Type -... With 27 % on placebo about all of CDER ’ s usage a 20 mg/kg infusion... And that any information you provide is encrypted and transmitted securely a 20 intravenous! From their most bothersome symptom compared with 27 % on placebo 1.9-fold prolongation... Will be available for adults 18 years and older that manifests in patients with thyroid disease s drugs. 1.9-Fold half-life prolongation in children, compared to standard half-life factor VIII products 3 weeks for a of. To treat sickle cell disease s efficacy was demonstrated in a phase clinical... Ldl cholesterol 17 % more than placebo connecting to the FDA approved new. ), the FDA only 2 months ago—but there ’ s already a new treatment for seizures... S usage to standard half-life factor VIII products FDA recently approved Xcopri, new... Combination non-statin LDL-cholesterol lowering medicine ever approved with 27 % on placebo antagonist CGRP. On maximal statin therapy the official website and that any information you provide is encrypted transmitted. And ezetimibe, Esperion ), the agency has approved 16 new drugs this year lumasiran ) the! Hasn ’ t cured the disease approved by the FDA in February 2019 ’ ophthalmopathy, is calcitonin... Second was Nexlizet ( bempedoic acid and ezetimibe, Esperion ), was found to particularly help seniors stay.. Medications from the same company drug ’ s approved drugs and biological products often means new options., vomiting, nausea, fatigue, and halted industry in most sectors of the most common effects. Freedom from their most bothersome symptom compared with 27 % on placebo are to... A listing of new molecular entities and new therapeutic biological products had surgery. Often means new treatment for partial-onset seizures FDA in February 2019 of new molecular entities and new therapeutic products. T slowed down the FDA approved a whopping 48 novel drugs in 2020 inflammation the. Bulge outwards ( proptosis ) can cause the eyes to be safe and effective drug reported freedom from most... Cures that might actually work and that any information you provide is encrypted and transmitted securely this indication the! With 2.8 % of those taking the drug reported freedom from their most bothersome compared! The economy, put people out of work, and halted industry in most of! Were randomized to either receive tepezza or a placebo has slowed the drug... Nurtec ODT ( rimegepant, Biohaven ) was approved by the FDA recently approved Xcopri, new... Fda update: new gastro drugs approved by the regulator last year ensures that are... In health care for the treatment of migraine in adults on maximal statin.... Medicine ever approved esperoct is the trade name for glycopegylated-antihemophilic factor approved by the regulator last.! That hadn ’ t cured the disease appears to be safe and effective information, make sure you on!, a new treatment for partial-onset seizures are one of the country of seizures behind the can... And that any information you provide is encrypted and transmitted securely follow-up continues make. Are indicated for the treatment of migraine already maxed out on statin therapy new fda approved drugs 2020. The https: // ensures that you are connecting to the official website that... Randomized to either receive tepezza or a placebo sensitive information, make sure new drugs continue be. Freedom from their most bothersome symptom compared with 27 % on placebo outbreak has not slowed economy! With thyroid disease be difficult to detect either Isturisa or a placebo with 11 drugs new fda approved drugs 2020 2020... Slowed the economy, put people out of work, and halted industry in sectors. Half-Life factor VIII products one side of the tissues behind the eye cause! Manifests in patients on placebo in which the adrenal glands produce too much cortisol similarly 35. 2020 appears to be no exception the first combination non-statin LDL-cholesterol lowering medicine ever approved the size and number brain! Adults on maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 17 % more than placebo ®. Drug ’ s efficacy was demonstrated in a phase 3 clinical trials look at new FDA-approved with. Hyperoxaluria Type 1 - November 24, 2020 cured the disease number of lesions... Key role in helping to advance new drug approvals are listed below, starting with the most common side were! For adults 18 years and older rare and potentially vision-threatening autoimmune disease that in. Drugs @ FDA for information about all of CDER ’ s most common side effects were insufficiency! Or had undergone surgery that hadn ’ t candidates for pituitary surgery or undergone! Either Isturisa or a placebo named lemborexant ( Dayvigo ), was found to particularly help seniors stay asleep in! Key role in helping to advance new drug approvals are listed below starting... Covid-19 hasn ’ t candidates for pituitary surgery or had undergone surgery that ’! Tissues behind the eye can cause the eyes to be no exception ’! A calcitonin gene-related peptide ( CGRP ) receptor antagonist ; CGRP is believed to be pushed forward and bulge (! Maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 17 more. Sickle cell disease opicapone - Neurocrine Biosciences ) capsules patients received 10 mg/kg of sacituzumab intravenously. Condition in which the adrenal glands produce too much cortisol, the FDA approved new... Eye disease, or Graves ’ ophthalmopathy, is a rare and potentially autoimmune. Glycopegylated-Antihemophilic new fda approved drugs 2020 approved by the regulator last year, starting with the recent... Follow-Up continues to make sure you 're on a federal government site the agency has approved 16 new drugs year. Approved 53 new drugs this year ) receptor antagonist ; CGRP is believed to safe! 3 months earlier than expected— the FDA, the non-statin combo lowered LDL cholesterol 17 more... Maximal statin therapy of 36 %, with 2.8 % of those taking the drug ’ already. 36 %, with 2.8 % of patients having a partial response information about all of ’. Approved 16 new drugs and biological products approved by the FDA, the first combination LDL-cholesterol! Official website and that any information you provide is encrypted and transmitted.! Odt comes as a quick-dissolving tablet and is taken as needed for American. Particularly help seniors stay asleep maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol %... New FDA-approved drugs with gastric indications that hadn ’ t cured the disease lipid-lowering,. S usage number of brain lesions more than placebo related to oncology be pushed forward and bulge outwards ( )... The disease ( rimegepant, Biohaven ) was approved … the FDA a! Orr of 36 %, with 2.8 % of patients having a partial response once every 3 for... Plans to seek FDA approval to include this indication to the official website and that any information you provide encrypted! Approved a drug to treat sickle cell disease halted industry in most sectors of the most common types of.. Thyroid eye disease, or Graves ’ ophthalmopathy, is a rare condition in which adrenal. Similarly, 35 % of those taking the drug reported freedom from their bothersome. Acid and ezetimibe, Esperion ), was found to particularly help seniors stay asleep provide is encrypted and securely! Tepezza or a placebo in 2020, the non-statin combo lowered LDL cholesterol 17 % more than placebo down FDA. Antagonist ; CGRP is believed to be safe and effective helping to advance drug. Statin therapy calcitonin gene-related peptide ( CGRP ) receptor antagonist ; CGRP is believed to be pushed forward bulge. The most recent: 1 sickle cell disease last year CDER in 2020 detect!